English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objective  A subset analysis of the randomised, phase 3,  MDS ‐004 study to evaluate outcomes in patients with  I nternational  P rognostic  S coring  S ystem ( IPSS )‐defined  L ow‐/ I ntermediate ( I nt)‐1‐risk myelodysplastic syndromes ( MDS ) with isolated del(5q).    Methods  Patients received lenalidomide 10 mg/d (days 1–21;  n  =   47) or 5 mg/d (days 1–28;  n  = 43) on 28‐d cycles or placebo ( n  =   45). From the placebo and lenalidomide 5 mg groups, 84% and 58% of patients, respectively, crossed over to lenalidomide 5 or 10 mg at 16 wk, respectively.    Results  Rates of red blood cell‐transfusion independence ( RBC ‐ TI ) ≥182 d were higher in the lenalidomide 10 mg (57.4%;  P  <   0.0001) and 5 mg (37.2%;  P  = 0.0001) groups vs. placebo (2.2%). Cytogenetic response rates (major + minor responses) were 56.8% ( P  < 0.0001), 23.1% ( P  = 0.0299) and 0%, respectively. Two‐year cumulative risk of acute myeloid leukaemia progression was 12.6%, 17.4% and 16.7% in the lenalidomide 10 mg, 5 mg, and placebo groups, respectively. In a 6‐month landmark analysis, overall survival was longer in lenalidomide‐treated patients with  RBC ‐ TI  ≥182 d vs. non‐responders ( P  = 0.0072). The most common grade 3–4 adverse event was myelosuppression.    Conclusions  These data support the clinical benefits and acceptable safety profile of lenalidomide in transfusion‐dependent patients with  IPSS ‐defined  L ow‐/ I nt‐1‐risk  MDS  with isolated del(5q).

european journal of haematology

Outcomes in  RBC  transfusion‐dependent patients with  L ow‐/ I ntermediate‐1‐risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the  MDS ‐004 study